Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093343 | 1.00 | NAPRT (0.60) | NAPRTGSK3BGRM4PTPN1RAB9A | |
| Hydrochloric Acid SCHEMBL8788570 | 0.98 | NAPRT (0.58) | NAPRTGSK3BGRM4PTPN1RAB9A | |
| SCHEMBL1985578 | 0.84 | NAPRT (0.64) | NAPRTGRM4RAB9AL3MBTL1MAPT | |
| SCHEMBL6439911 | 0.82 | NAPRT (0.62) | NAPRTGRM4RAB9AL3MBTL1MAPT | |
| SCHEMBL4899048 | 0.82 | NAPRT (0.62) | NAPRTGSK3BGRM4RAB9AL3MBTL1 | |
| SCHEMBL6389786 | 0.81 | NAPRT (0.60) | NAPRTGRM4RAB9AL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL4894083 | 0.81 | NAPRT (0.60) | NAPRTGSK3BGRM4RAB9AL3MBTL1 | |
| SCHEMBL30175321 | 0.81 | NAPRT (0.60) | NAPRTGRM4RAB9AL3MBTL1MAPT | |
| SCHEMBL1877325 | 0.81 | NAPRT (0.60) | NAPRTGRM4RAB9AL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL12098974 | 0.79 | NAPRT (0.58) | NAPRTGRM4RAB9AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | claimed |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| EP-4265613-A1 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3461827-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2054060-A1 | FLUORINATED LIGANDS FOR TARGETING PERIPHERAL BENZODIAZEPINE RECEPTORS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2009-05-06 | — | — | EP | disclosed |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2008-12-04 | — | — | US | disclosed |
| WO-2008145596-A1 | PIPERIDINE-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008022396-A1 | FLUORINATED LIGANDS FOR TARGETING PERIPHERAL BENZODIAZEPINE RECEPTORS | AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) | 2008-02-28 | — | — | WO | disclosed |
| EP-1467981-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | Kylix Pharmaceuticals B.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062215-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | KYLIX PHARMACEUTICALS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
| US-5714506-A | ALSO FOR REDUCING LEVELS OF TRIGLYCERIDES AND CHOLESTEROL OR TREATING ATHEROSCLEROSIS | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5561142-A | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NAPRT 2031/4885GSK3B 665/4885GRM4 4355/4885 |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | NAPRT 996/4885GSK3B 4125/4885GRM4 3592/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | NAPRT 1333/4885GSK3B 2559/4885GRM4 22/4885 |
| US-20080300279-A1 | PIPERIDINE-AMIDE DERIVATIVES | CPT1A, CPT1B, CPT2 | NAPRT 663/4885GSK3B 4011/4885GRM4 3485/4885 |
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | NAPRT 1333/4885GSK3B 2559/4885GRM4 22/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | NAPRT 1333/4885GSK3B 2559/4885GRM4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.